신경외과용 의료기기 시장 : 시장 예측(2026-2032년)

The Neurosurgery Devices Market is projected to grow by USD 33.12 billion at a CAGR of 10.46% by 2032.

Neurosurgery Devices Executive Summary: Precision, Safety, and Digital Integration

Neurosurgery devices are becoming central to modern neurological care as health systems face rising clinical demand from traumatic brain injury, stroke, brain tumors, hydrocephalus, epilepsy, Parkinson's disease, spinal disorders, and other complex central nervous system conditions. The category spans neurostimulation systems, stereotactic and navigation platforms, neuroendoscopy tools, cranial fixation systems, cerebrospinal fluid management devices, neurosurgical drills and microscopes, neurovascular devices, ultrasonic aspirators, robotic-assisted platforms, and intraoperative monitoring technologies. Adoption is being shaped by the shift toward minimally invasive neurosurgery, image-guided intervention, precision targeting, and improved perioperative safety. Regulatory scrutiny remains high because these devices are often implantable, life-sustaining, or used in critical neuroanatomical procedures, making clinical evidence, biocompatibility, cybersecurity, and post-market surveillance essential. Demand is also influenced by the increasing use of advanced imaging, hybrid operating rooms, interventional neuroradiology, and multidisciplinary care pathways. As hospitals prioritize shorter procedure times, reduced complications, and better functional outcomes, neurosurgery device strategies are moving beyond hardware performance toward integrated procedural ecosystems that combine imaging, navigation, planning software, robotics, AI-enabled decision support, and longitudinal patient monitoring.

Transformative Shifts Reshaping Neurosurgery Device Adoption

The neurosurgery devices landscape is undergoing a structural transformation driven by minimally invasive techniques, real-time imaging, and connected surgical platforms. Traditional open neurosurgical workflows are being complemented by endoscopic, catheter-based, stereotactic, and robotic-assisted approaches that aim to reduce tissue disruption and improve targeting accuracy. Navigation systems are increasingly integrated with MRI, CT, angiography, tractography, and intraoperative ultrasound, allowing clinicians to visualize lesions, functional pathways, vascular structures, and implant trajectories with greater confidence. Neurovascular intervention continues to expand as mechanical thrombectomy, aneurysm management, embolization, and flow diversion technologies reshape the treatment of acute and chronic cerebrovascular disease. Implantable neuromodulation is also evolving, with deep brain stimulation, responsive stimulation, spinal cord stimulation, and peripheral nerve stimulation benefiting from improved programming, rechargeable systems, closed-loop sensing, and patient-specific therapy settings. At the same time, procurement decisions are shifting toward platforms that support interoperability, surgeon training, remote collaboration, sterilization efficiency, and evidence-based clinical protocols. The competitive environment is increasingly influenced by regulatory compliance, clinical data quality, manufacturing resilience, and the ability to support hospitals through education, maintenance, software updates, and procedural workflow optimization.

Cumulative Impact of Artificial Intelligence on Neurosurgery Devices

Artificial intelligence is adding a new layer of intelligence across the neurosurgery device value chain, from preoperative planning to postoperative follow-up. In surgical planning, AI-enabled image segmentation can support identification of tumors, hemorrhage, ventricular anatomy, vascular lesions, and eloquent brain regions, helping teams refine access routes and reduce avoidable risk. Intraoperatively, machine learning can enhance navigation accuracy, support microscope and endoscope visualization, assist robotic positioning, and analyze neurophysiological signals during functional mapping and monitoring. In neurovascular care, AI-based imaging triage has demonstrated utility in accelerating stroke workflow by flagging large vessel occlusion, perfusion mismatch, and hemorrhage patterns for time-sensitive intervention. For implantable neuromodulation, AI and advanced algorithms are enabling adaptive stimulation, symptom-state detection, and therapy personalization using physiologic signals and patient-reported outcomes. The cumulative impact is a move toward data-rich neurosurgical ecosystems that combine imaging, device telemetry, electronic health records, and clinical decision support. However, adoption depends on explainability, validation across diverse patient populations, cybersecurity safeguards, regulatory alignment, and clinician oversight. Industry leaders must treat AI not as a standalone feature but as a clinically governed capability embedded into safe, auditable, and interoperable neurosurgery workflows.

Key Regional Insights Across Global Neurosurgery Device Markets

Europe benefits from structured regulatory oversight, academic neurosurgery networks, universal or publicly supported healthcare systems, and strong uptake of image-guided surgery, neuromodulation, neurovascular care, and stereotactic procedures, while procurement timelines and health technology assessment requirements place clear emphasis on evidence, safety, traceability, and cost-effectiveness. Asia-Pacific is experiencing rapid neurosurgery device modernization due to expanding tertiary hospital networks, increasing stroke and trauma care capacity, and growing investment in advanced imaging, robotic surgery, and interventional neuroradiology. China, Japan, India, South Korea, and Australia are important drivers of neurosurgical technology adoption, though access varies significantly between metropolitan centers and rural regions. North America remains highly influential because of strong specialized neurosurgery programs, established reimbursement pathways for many advanced procedures, robust clinical trial activity, and broad use of navigation, neuromodulation, neurovascular intervention, and intraoperative imaging. Latin America is gradually strengthening neurosurgical capacity, with Brazil and Mexico leading adoption in large urban hospitals while public-sector budget constraints, import dependency, and uneven specialist availability continue to affect access. The Middle East is investing in advanced hospital infrastructure, specialist centers, and medical technology modernization, particularly in Gulf economies, with neurosurgery device adoption linked to national healthcare transformation programs and international clinical partnerships. Africa presents substantial unmet need in trauma, hydrocephalus, epilepsy, congenital conditions, and tumor care, but adoption is constrained by limited neurosurgical workforce density, imaging availability, operating room resources, maintenance infrastructure, and affordability; nonetheless, training partnerships, telemedicine, and targeted investments are improving access in selected urban referral centers.

Key Group Insights for Neurosurgery Device Strategy

NATO member countries include several of the world's most advanced military and civilian trauma systems, where neurosurgery device demand is connected to traumatic brain injury management, neurocritical care, rehabilitation pathways, surgical readiness, and resilient medical supply chains. G7 countries generally demonstrate mature neurosurgery device utilization due to advanced hospital systems, specialist density, clinical research infrastructure, and established pathways for complex cranial, spinal, neurovascular, and functional neurosurgery. The European Union emphasizes patient safety, clinical evidence, traceability, and post-market performance under stringent medical device regulation, creating a strong environment for validated neurosurgery technologies while requiring manufacturers to maintain robust clinical documentation and quality systems. BRICS economies represent a diverse growth environment, with Brazil, Russia, India, China, and South Africa each balancing demand for advanced neurosurgical care against access disparities, domestic manufacturing priorities, public procurement rules, and regional healthcare capacity gaps. ASEAN countries are advancing neurosurgery device adoption through expanding hospital infrastructure, broader access to CT and MRI, and rising demand for stroke, trauma, spine, and brain tumor care, although procurement capacity and specialist availability differ widely across member states. The GCC is characterized by substantial investment in advanced tertiary hospitals, international accreditation, digital health programs, and specialist recruitment, supporting adoption of high-end neurosurgical navigation, robotics, neurovascular platforms, and neuromodulation technologies.

Key Country Insights Shaping Neurosurgery Device Demand

The United States is a major center for neurosurgery device innovation and clinical adoption, supported by high procedure volumes, specialist hospitals, advanced imaging availability, and strong use of neurovascular, neuromodulation, navigation, and robotic-assisted technologies. China is rapidly scaling neurosurgical capacity through hospital modernization, domestic device development, stroke-center expansion, and increasing investment in robotic and digital surgery. Germany has a highly developed hospital infrastructure, substantial neurosurgical specialization, and strong adoption of navigation, intraoperative imaging, neurovascular intervention, and functional neurosurgery technologies. Japan's neurosurgery device environment is highly sophisticated, with strong use of neurovascular technologies, stereotactic approaches, imaging, and functional neurosurgery supported by an aging population and advanced hospital systems. India faces high unmet need across neurotrauma, stroke, congenital disorders, spine disease, and tumors, with advanced device adoption concentrated in metropolitan private and tertiary public institutions. The United Kingdom's adoption is influenced by national care pathways, specialist neuroscience centers, and structured health technology evaluation, with strong emphasis on clinical evidence and cost-effectiveness. Canada's neurosurgery environment is shaped by universal healthcare delivery, regional referral networks, and evidence-based procurement, with access influenced by provincial budgets and wait-time management. France combines advanced academic neurosurgery, neurovascular expertise, and reimbursement oversight, supporting adoption where devices demonstrate clear clinical value. Brazil has one of Latin America's largest neurosurgical bases, with strong demand for trauma, stroke, tumor, spine, and hydrocephalus care, although import costs and public-sector resource limitations remain relevant. Mexico is expanding advanced neurosurgical capabilities in major urban centers, while disparities between private and public systems affect access to high-cost implants and capital equipment. Australia benefits from strong specialist referral networks, high clinical standards, and adoption of advanced navigation, neurovascular, and neuromodulation technologies in major centers. Italy and Spain have well-established neurosurgery networks, with adoption shaped by regional healthcare administration, academic centers, and demand for minimally invasive and image-guided procedures. South Korea is a technologically advanced market with strong hospital digitalization, neurosurgical expertise, robotic surgery interest, and rapid integration of imaging-guided and minimally invasive approaches. Russia maintains significant neurosurgical capability in major centers, though technology access can vary by region and is affected by procurement and supply chain considerations.

Actionable Recommendations for Neurosurgery Device Leaders

Industry leaders should prioritize clinically validated innovation that improves procedural accuracy, reduces complications, and supports measurable patient outcomes. Product development should focus on interoperability with imaging, navigation, robotics, electronic health records, and hospital cybersecurity frameworks, as neurosurgery teams increasingly prefer integrated procedural ecosystems over isolated devices. Manufacturers and solution providers should invest in surgeon education, simulation-based training, proctoring models, and service infrastructure, particularly in emerging regions where workforce development and maintenance capacity directly influence adoption. Regulatory strategy must be proactive, with strong clinical evidence plans, post-market surveillance, human factors validation, software lifecycle governance, and AI transparency where digital decision support is embedded. Supply chain resilience should be strengthened through dual sourcing, component traceability, sterilization compatibility, and regional service capabilities. Commercial strategies should align with hospital value priorities, including operating room efficiency, length-of-stay reduction, complication avoidance, device durability, and total cost of ownership. In emerging healthcare systems, modular platforms, scalable configurations, financing support, and training partnerships can improve access while maintaining safety standards. For AI-enabled neurosurgery devices, leaders should emphasize explainability, clinician control, bias assessment, privacy protection, and real-world performance monitoring.

Research Methodology Based on Verified Industry Evidence

This executive summary is developed using a secondary research methodology focused on verified public-domain and institutionally credible sources. The analysis draws on medical device regulatory guidance, peer-reviewed neurosurgery and neurointerventional literature, public health data on neurological disease burden, clinical practice guidelines, hospital technology adoption patterns, reimbursement and health technology assessment frameworks, and documented trends in imaging, neuromodulation, neurovascular intervention, robotics, and AI-enabled surgical support. Regional, group, and country insights are synthesized from healthcare infrastructure indicators, specialist capacity trends, regulatory environments, public procurement dynamics, and published evidence on neurological care access. The methodology excludes market sizing, market share calculation, financial forecasting, and speculative estimates. Insights are triangulated across multiple source types to ensure consistency, relevance, and evidence alignment, while narrative interpretation is limited to observable industry developments and data-supported healthcare trends. The research approach emphasizes clinical utility, regulatory readiness, technology adoption drivers, access barriers, and strategic implications for stakeholders across the neurosurgery devices ecosystem.

Conclusion: The Future of Neurosurgery Devices Is Integrated and Evidence-Led

Neurosurgery devices are entering a new phase defined by precision intervention, digital integration, AI-assisted workflow support, and increasing demand for safer, less invasive neurological care. Hospitals and clinicians are seeking technologies that enhance visualization, navigation, tissue preservation, implant performance, neurophysiological monitoring, and treatment personalization. Regional adoption will continue to depend on specialist capacity, imaging infrastructure, reimbursement, regulatory requirements, procurement priorities, and training ecosystems. Mature healthcare systems are advancing integrated surgical platforms and AI-enabled capabilities, while emerging markets are focused on expanding essential neurosurgical access and scalable advanced care. Industry leaders that combine robust clinical evidence, interoperable design, regulatory excellence, service reliability, and education-driven adoption will be best positioned to support the evolving needs of neurosurgeons and patients. The most durable opportunities will come from solutions that demonstrate clear clinical value, improve workflow efficiency, and maintain trust in high-stakes neurological procedures.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neurosurgery Devices Market, by Product Type

• 7.1. Introduction
• 7.2. Neurostimulation Devices
  • 7.2.1. Spinal Cord Stimulators
  • 7.2.2. Deep Brain Stimulators
  • 7.2.3. Vagus Nerve Stimulators
• 7.3. Neurointerventional Devices
  • 7.3.1. Cerebral Aneurysm Coils
  • 7.3.2. Neurovascular Stents
• 7.4. Surgical Navigation Systems
  • 7.4.1. Image-Guided Navigation Systems
  • 7.4.2. Electromagnetic (EM) Navigation
  • 7.4.3. Robotic-Assisted Navigation
  • 7.4.4. Intraoperative Mapping Systems
• 7.5. Endoscopes
• 7.6. Implantable Devices

8. Neurosurgery Devices Market, by Procedure Type

• 8.1. Introduction
• 8.2. Endoscopic Surgery
• 8.3. Laser Therapy
• 8.4. Open Surgery

9. Neurosurgery Devices Market, by Patient Type

• 9.1. Introduction
• 9.2. Adult Patients
• 9.3. Pediatric Patients
• 9.4. Geriatric Patients

10. Neurosurgery Devices Market, by Application

• 10.1. Introduction
• 10.2. Tumor Surgery
• 10.3. Epilepsy
• 10.4. Vascular / Stroke Treatment
• 10.5. Hydrocephalus Treatment
• 10.6. Trauma & Emergency Neurosurgery
• 10.7. Spinal Cord Disorders

11. Neurosurgery Devices Market, by End User

• 11.1. Introduction
• 11.2. Hospitals & Specialty Clinics
• 11.3. Ambulatory Surgical Centers
• 11.4. Research & Academic Institutes

12. Neurosurgery Devices Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Direct Sales
• 12.3. Online Sales
• 12.4. Distributors

13. Neurosurgery Devices Market, by Region

• 13.1. Europe
• 13.2. Asia-Pacific
• 13.3. North America
• 13.4. Latin America
• 13.5. Middle East
• 13.6. Africa

14. Neurosurgery Devices Market, by Group

• 14.1. NATO
• 14.2. G7
• 14.3. European Union
• 14.4. BRICS
• 14.5. ASEAN
• 14.6. GCC

15. Neurosurgery Devices Market, by Country

• 15.1. United States
• 15.2. China
• 15.3. Germany
• 15.4. Japan
• 15.5. India
• 15.6. United Kingdom
• 15.7. Canada
• 15.8. France
• 15.9. Brazil
• 15.10. Mexico
• 15.11. Australia
• 15.12. Italy
• 15.13. South Korea
• 15.14. Russia
• 15.15. Spain

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Medtronic PLC
• 17.2. Johnson & Johnson Services, Inc.
• 17.3. Stryker Corporation
• 17.4. Boston Scientific Corporation
• 17.5. Zimmer Biomet Holdings, Inc.
• 17.6. Abbott Laboratories
• 17.7. Danaher Corporation
• 17.8. B. Braun AG
• 17.9. Koninklijke Philips N.V.
• 17.10. Siemens Healthineers AG
• 17.11. Olympus Corporation
• 17.12. Terumo Corporation
• 17.13. LivaNova PLC
• 17.14. Natus Medical Incorporated
• 17.15. Integra LifeSciences Corporation
• 17.16. KLS Martin SE & Co. KG
• 17.17. NAKANISHI INC.
• 17.18. Accuray Incorporated
• 17.19. Renishaw plc
• 17.20. ASAHI INTECC CO., LTD.
• 17.21. Globus Medical, Inc.
• 17.22. Synaptive Medical Inc.
• 17.23. ClearPoint Neuro, Inc.
• 17.24. Adeor Medical AG
• 17.25. Brainlab SE
• 17.26. Elekta AB
• 17.27. iVascular S.L.U.
• 17.28. Luciole Medical AG
• 17.29. NeuroPace, Inc.
• 17.30. NuVasive, Inc.
• 17.31. Rebstock Instruments GmbH
• 17.32. Route 92 Medical, Inc.
• 17.33. Scientia Vascular, Inc.